Related Experiment Video

Updated: Jun 3, 2026

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
10:01

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

Published on: March 31, 2022

Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA)

Sarah J Lagedrost1, Martin St John Sutton, Meryl S Cohen

  • 1Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA.

American Heart Journal
|March 12, 2011
PubMed

Insights

Idebenone did not improve cardiac function or reduce left ventricular hypertrophy in pediatric Friedreich ataxia (FRDA) patients over a 6-month period. This study found no evidence of idebenone benefit for FRDA cardiac measures.

Area of Science:

  • Neurology
  • Cardiology
  • Genetics

Background:

  • Friedreich ataxia (FRDA) is frequently linked to hypertrophic cardiomyopathy, but its characteristics and treatment are poorly understood.
  • This study investigated the cardiac manifestations and potential treatment of FRDA.

Purpose of the Study:

  • To determine if idebenone improves cardiac measures in pediatric patients with Friedreich ataxia.
  • To assess the efficacy of idebenone in reducing left ventricular hypertrophy and improving cardiac function in FRDA.

Main Methods:

  • A 6-month randomized, double-blind, controlled study involving 70 pediatric subjects with FRDA.
  • Subjects received either idebenone (at varying doses) or a placebo, with electrocardiograms (ECGs) and echocardiograms performed.
  • Cardiac function was assessed using left ventricular (LV) mass index, ejection fraction (EF), and ECG parameters.

Main Results:

  • 90% of subjects exhibited ECG abnormalities, and 81.4% had left ventricular hypertrophy.
  • Baseline cardiac measures like LV mass index and EF showed some correlation with GAA repeat length but were not clearly predicted by it.
  • Idebenone treatment did not significantly improve LV mass index, EF, or ECG parameters compared to placebo.

Conclusions:

  • Idebenone demonstrated no significant benefit in decreasing left ventricular hypertrophy or enhancing cardiac function in pediatric FRDA patients over 6 months.
  • The study provides no evidence supporting the use of idebenone for improving cardiac measures in this FRDA cohort within the studied timeframe.
Abstract

More Related Videos

Single-Cell Optical Action Potential Measurement in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes08:39

Single-Cell Optical Action Potential Measurement in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Published on: December 22, 2020

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...